Neurocrine Biosciences has announced plans to acquire Soleno Therapeutics for $2.9 billion. The deal centers on Vykat XR, recently approved as a treatment for Prader-Willi syndrome-related hunger symptoms. Analysts see strategic benefits but note surprise at the sale price.
